Skip to content

axabio

Active
Public limited companyfounded 2024active for 2 yearsNieuwe dreef 2, 2620 Hemiksem, BelgiumKBO/BCE: BE 1011.997.238
Summary

The computed 12-month bankruptcy probability of axabio is 1.5% (moderate). The 2025 annual accounts show negative equity (-€652,510) and a net result of -€2.4m. Its solvency ranks better than 9% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Activity
Research and development on biotechnology
NACE 72101Manufacture of chemicals and chemical products NACE 20140
Largest company by total assets in Hemiksem, Professional and technical services sector1 site
Size
€1.4moperating revenue 2025
Staff
11.1 FTE
Equity
-€652,510
Loss
-€2.4m
Financial health
54 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
1.5%
Structure
Parent
PROVIRON CAPITAL · 93.03%
Auditor: Finvision Bedrijfsrevisoren2025 accounts 42 days early
Why 54raises riskCapped at 59: negative equityLiquidity: current ratio 2.21, cash €1,368, halvedLoss of €2.4m, the second in a row (financial year 2025)lowers riskFounded in 2024Sector: Scientific research and development (NACE 72)Show the evidence

Checked score

Score 2025
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 26% of its sector peers (NACE 72, small)
Negative equity caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Weak
Solvency 9-41
equity -16.4% of total assets
Liquidity 49-4
short-term debt 11.6% · cash 0.0%
Profitability 0=
return on assets -59.6%
Bankruptcy probability, 12 months
1.5% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (165 companies, NACE 72, small)
Last 24 months 08-2025: 1.0%lowest value 09-2025: 1.0%● unchanged vs 08-2025lowest value 10-2025: 1.0%● unchanged vs 09-2025 11-2025: 1.0%● unchanged vs 10-2025 12-2025: 1.0%● unchanged vs 11-2025 01-2026: 1.0%● unchanged vs 12-2025 02-2026: 1.0%● unchanged vs 01-2026 03-2026: 1.2%▲ +0.2 percentage points vs 02-2026 04-2026: 1.3%▲ +0.1 percentage points vs 03-2026 05-2026: 1.2%▼ -0.1 percentage points vs 04-2026 06-2026: 1.3%▲ +0.1 percentage points vs 05-2026 07-2026: 1.6%▲ +0.3 percentage points vs 06-2026highest value 08-2026: 1.5%▼ -0.1 percentage points vs 07-2026 09-2026: 1.5%● unchanged vs 08-2026 10-2026: 1.5%● unchanged vs 09-2026
No credit on open account
Liquidity ample (current ratio 2.21, compared with 0.78 in 2024, above the usual 1.5; short-term debt: 11.6% and cash: 0% of total assets), but equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 7% on solvency, 35% on liquidity, 11% on profitability and 50% on growth.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Founded in 2024
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Sector: Scientific research and development (NACE 72)
KBO
raises risk · Liquidity: current ratio 2.21, cash €1,368, halved
NBB · annual accounts
raises risk · Loss of €2.4m, the second in a row (financial year 2025)
NBB · annual accounts
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
2425
2024 to 2025 · latest year -€652,510
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 19-06-2026, 42 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
42 days early
2024
56 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 2 accounts on average 49 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
29-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2024.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · full…
  2. Liquidity more than doubledcurrent ratio 2.21
  3. Resignation: BDO Bedrijfsrevisoren (statutory auditor)Permanent representative: Veerle Catry ·…

Financials · financial year 2025, full format

Turnover
€384,292▲ 762%
2024 · €44,560
EBIT margin
Not meaningful: turnover is only a small part of operating income
Net result
-€2.4m▼ 2.6%
2024 · -€2.3m
Working capital
€560,427
2024 · -€70,585
Trend over the years

2024 to 2025, 2 financial years

The operating result stays negative: a loss of €2.5m in 2025 against €2.3m in 2024; the loss grows.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€0.4m 2025 Operating result-€2.5m 2025 Net result-€2.4m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line20242025
Turnover€0.04m-€0.4m▲ 762%
Operating result-€2.3m--€2.5m▼ 9.1%
Net result-€2.3mbelow the sector's middle half--€2.4mbelow the sector's middle half▼ 2.6%
Equity€0.8mwithin the sector's middle half--€0.7mbelow the sector's middle half
Total assets€3.2mwithin the sector's middle half-€4.0mwithin the sector's middle half▲ 24.6%
Debt€2.4m-€4.6m▲ 93.7%
Working capital-€0.07mbelow the sector's middle half-€0.6mwithin the sector's middle half
Solvency25.2%within the sector's middle half--16.4%below the sector's middle half▼ 41.6pp
Current ratio0.78below the sector's middle half-2.21within the sector's middle half▲ 1.43
Return on assets (ROA)-72.3%below the sector's middle half--59.6%below the sector's middle half▲ 12.8pp
Staff (FTE)10.4within the sector's middle half-11.1within the sector's middle half▲ 6.7%
above within below the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.0m
Fixed assets €3.0m ▲ 0.6%
Current assets €1.0m ▲ 302%
Equity and liabilities
Equity-€652,510
Debt€4.6m
Equity is negative: debt (€4.6m) exceeds the balance-sheet total (€4.0m).
Key figures and ratios
2025 value · change against 2024
EBITDA
-€1.6m▼
2024 · -€1.5m
Cash flow
-€1.5m▲
2024 · -€1.6m
Quick ratio
1.75▲
2024 · 0.69
Interest coverage
-13.88▲
2024 · -42.00
Debt ≤ 1 year
€462,941▲
2024 · €325,297
Debt > 1 year
€4.2m▲
2024 · €2.1m
Staff costs
€1.1m▲
2024 · €635,211
No debt to equity: equity is negative, so debt divided by equity means nothing.
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 490 companies that looked in July 2024 the way this one looks now, 6.7% went bankrupt within 24 months and 88.8% are still going.

  • Small
  • 2 to 5 years old
  • negative equity
  • a loss of 10% of the balance sheet or more
6.7% went bankrupt
3.9% stopped otherwise
88.8% still going

A further 0.6% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 1.5% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 490 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 67 lines
Balance sheet Code20242025
Assets
Total assets20/58€3.2m€4.0m▲
Fixed assets21/28€2.9m€3.0m▲
Intangible fixed assets21€0.3m€0.7m▲
Tangible fixed assets22/27€2.6m€2.2m▼
Plant, machinery and equipment23€2.6m€2.2m▼
Furniture and vehicles24€0.008m€0.01m▲
Current assets29/58€0.3m€1.0m▲
Stocks and contracts in progress3€0.03m€0.2m▲
Stocks30/36€0.03m€0.2m▲
Raw materials and consumables30/31€0.03m€0.2m▲
Amounts receivable within one year40/41€0.1m€0.8m▲
Trade receivables40€0.04m€0.2m▲
Other amounts receivable41€0.09m€0.6m▲
Cash at bank and in hand54/58€0.09m€0.001m▼
Deferred charges and accrued income490/1€0.006m€0.02m▲
Equity and liabilities
Total equity and liabilities10/49€3.2m€4.0m▲
Equity10/15€0.8m-€0.7m▼
Contributions10/11€3.1m€3.1m=
Capital10€3.1m€3.1m=
Issued capital100€3.1m€3.1m=
Reserves13€0.04m€0.04m=
Non-distributable reserves130/1€0.02m€0.02m=
Legal reserve130€0.02m€0.02m=
Distributable reserves133€0.02m€0.02m=
Profit (loss) carried forward14-€2.3m-€4.7m▼
Investment grants15-€0.9m
Amounts payable17/49€2.4m€4.6m▲
Amounts payable after more than one year17€2.1m€4.2m▲
Financial debts170/4€2.1m€4.2m▲
Other loans174€2.1m€4.2m▲
Amounts payable within one year42/48€0.3m€0.5m▲
Financial debts43€0.01m€0.01m▲
Credit institutions430/8€0.01m€0.01m▲
Trade debts44€0.3m€0.4m▲
Suppliers440/4€0.3m€0.4m▲
Taxes, remuneration and social security45€0.02m€0.1m▲
Taxes450/3-€3
Remuneration and social security454/9€0.02m€0.1m▲
Other amounts payable47/48€0.002m€0▼
Income statement Code20242025
Operating income70/76A€0.3m€1.4m▲
Turnover70€0.04m€0.4m▲
Own construction capitalised72€0.3m€0.6m▲
Other operating income74€0.02m€0.2m▲
Non-recurring operating income76A€0.002m€0.2m▲
Operating charges60/66A€2.6m€3.8m▲
Goods for resale, raw materials and consumables60€0.1m€0.5m▲
Purchases600/8€0.1m€0.7m▲
Change in stocks: decrease (increase)609-€0.03m-€0.2m▼
Services and other goods61€1.1m€1.3m▲
Remuneration, social security and pensions62€0.6m€1.1m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.7m€0.9m▲
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.002m€0▼
Other operating charges640/8€0.001m€0.001m▼
Operating profit (loss)9901-€2.3m-€2.5m▼
Financial income75/76B€381€0.2m▲
Recurring financial income75€381€0.2m▲
Other financial income752/9€381€0.2m▲
Financial charges65/66B€0.04m€0.1m▲
Recurring financial charges65€0.04m€0.1m▲
Debt charges650€0.04m€0.1m▲
Other financial charges652/9€0.002m€0.002m▲
Profit (loss) for the period before taxes9903-€2.3m-€2.4m▼
Profit (loss) for the period9904-€2.3m-€2.4m▼
Profit (loss) for the period to be appropriated9905-€2.3m-€2.4m▼
Appropriation of the result
Profit (loss) to be appropriated9906-€2.3m-€4.7m▼
Profit (loss) brought forward from the previous period14P--€2.3m
Social balance sheet
Average headcount (FTE)908710.411.1▲

The notes to these accounts (46 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20242025Change
Operating income70/76A€0.3m€1.4m▲ 319%
Turnover70€0.04m€0.4m▲ 762%
Own construction capitalised72€0.3m€0.6m▲ 116%
Other operating income74€0.02m€0.2m▲ 13×
Non-recurring operating income76A€0.002m€0.2m▲ 82×
Operating charges60/66A€2.6m€3.8m▲ 47.8%
Goods for resale, raw materials and consumables60€0.1m€0.5m▲ 450%
Purchases600/8€0.1m€0.7m▲ 458%
Change in stocks: decrease (increase)609-€0.03m-€0.2m▼ 485%
Services and other goods61€1.1m€1.3m▲ 14.2%
Remuneration, social security and pensions62€0.6m€1.1m▲ 78.7%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.7m€0.9m▲ 20.3%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€0.002m€0▼ 100%
Other operating charges640/8€0.001m€0.001m▼ 7.0%
Operating profit (loss)9901-€2.3m-€2.5m▼ 9.1%
Financial income75/76B€381€0.2m▲ 601×
Recurring financial income75€381€0.2m▲ 601×
Other financial income752/9€381€0.2m▲ 601×
Financial charges65/66B€0.04m€0.1m▲ 205%
Recurring financial charges65€0.04m€0.1m▲ 205%
Debt charges650€0.04m€0.1m▲ 215%
Other financial charges652/9€0.002m€0.002m▲ 23.8%
Profit (loss) for the period before taxes9903-€2.3m-€2.4m▼ 2.6%
Profit (loss) for the period9904-€2.3m-€2.4m▼ 2.6%
Profit (loss) for the period to be appropriated9905-€2.3m-€2.4m▼ 2.6%
Line20242025Change
Assets
Total assets20/58€3.2m€4.0m▲ 24.6%
Fixed assets21/28€2.9m€3.0m▲ 0.6%
Intangible fixed assets21€0.3m€0.7m▲ 145%
Tangible fixed assets22/27€2.6m€2.2m▼ 16.0%
Plant, machinery and equipment23€2.6m€2.2m▼ 16.2%
Furniture and vehicles24€0.008m€0.01m▲ 64.5%
Current assets29/58€0.3m€1.0m▲ 302%
Stocks and contracts in progress3€0.03m€0.2m▲ 585%
Stocks30/36€0.03m€0.2m▲ 585%
Raw materials and consumables30/31€0.03m€0.2m▲ 585%
Amounts receivable within one year40/41€0.1m€0.8m▲ 517%
Trade receivables40€0.04m€0.2m▲ 490%
Other amounts receivable41€0.09m€0.6m▲ 527%
Cash at bank and in hand54/58€0.09m€0.001m▼ 98.5%
Deferred charges and accrued income490/1€0.006m€0.02m▲ 174%
Equity and liabilities
Total equity and liabilities10/49€3.2m€4.0m▲ 24.6%
Equity10/15€0.8m-€0.7m-
Contributions10/11€3.1m€3.1m=
Capital10€3.1m€3.1m=
Issued capital100€3.1m€3.1m=
Reserves13€0.04m€0.04m=
Non-distributable reserves130/1€0.02m€0.02m=
Legal reserve130€0.02m€0.02m=
Distributable reserves133€0.02m€0.02m=
Profit (loss) carried forward14-€2.3m-€4.7m▼ 103%
Investment grants15-€0.9m-
Amounts payable17/49€2.4m€4.6m▲ 93.7%
Amounts payable after more than one year17€2.1m€4.2m▲ 102%
Financial debts170/4€2.1m€4.2m▲ 102%
Other loans174€2.1m€4.2m▲ 102%
Amounts payable within one year42/48€0.3m€0.5m▲ 42.3%
Financial debts43€0.01m€0.01m▲ 8.1%
Credit institutions430/8€0.01m€0.01m▲ 8.1%
Trade debts44€0.3m€0.4m▲ 21.8%
Suppliers440/4€0.3m€0.4m▲ 21.8%
Taxes, remuneration and social security45€0.02m€0.1m▲ 310%
Taxes450/3-€3-
Remuneration and social security454/9€0.02m€0.1m▲ 310%
Other amounts payable47/48€0.002m€0▼ 100%
Line20242025Change
Profit (loss) for the period9904-€2.3m-€2.4m▼ 2.6%
+ Depreciation and write-downs630€0.7m€0.9m▲ 20.3%
Operating cash flow (approximation)-€1.6m-€1.5m▲ 5.6%
Investment in fixed assets (approximation)--€0.9m-
Change in cash--€0.09m-

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (2)
Financial year Type Filed Reference
31-12-2025 full format 19-06-2026 2026-00175885
31-12-2024 full format 05-06-2025 2025-00125227

Similar companies · same sector, comparable size

Of the 760 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 483. 154 are within a factor 10 of this headcount. These 5 are the closest to it. See the whole sector

Subsidies and aid

Flemish government

2025 · 1 entry · €1.1m awarded · €608,000 paid
Schemes
1 entry · €1.1m · €608,000 paid · Fonds voor Innoveren en Ondernemen

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
1 director, 2 in day-to-day management, no change since 2024

Board 1

Wim MICHIELS
Chair · since 02-08-2024
Current

Day-to-day management 2

Mark Michiels
Managing director · since 02-08-2024
Current
Wim MICHIELS
Managing director · since 02-08-2024
Current

Statutory auditor 1

Finvision Bedrijfsrevisoren
Statutory auditor · since 03-12-2025 · permanent representative: Thomas Durieux
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

3 people since 2024, 3 in office
Show
  • Board
  • Day-to-day management
  • Statutory auditor
Mandates per person, with start and end dates
Name Functions and periods
Wim MICHIELS
  • Chair, from 02-08-2024 to date
  • Managing director, from 02-08-2024 to date
Mark Michiels
  • Managing director, from 02-08-2024 to date
Finvision Bedrijfsrevisoren
  • Statutory auditor, from 03-12-2025 to date
See the board, name and registered office on a given date →

Owners and capital

Owners

1 owner

Chain of control

  1. PROVIRON CAPITAL 93.03%
  2. axabio

Highest known parent: PROVIRON CAPITAL. The sources do not say who stands above it.

Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.

Capital and shareholders

Capital over the years
  1. 08-08-2024 Incorporation · €3,114,393.44 · 1,975,000 shares

Group and network

Connections & network

5 connected companies

History

Axabio was incorporated on 29 July 2024 as a public limited company, with a starting capital of €3.1m.12 Since 2024, Wim MICHIELS has served as chair of the company.3 The company has filed 2 sets of annual accounts, the latest for financial year 2025.4

  1. 1KBO register
  2. 2Belgian Official Gazette, 08-08-2024
  3. 3Belgian Official Gazette, 14-03-2025
  4. 4National Bank, annual accounts 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
19-06
NBB filing Annual accounts filed
financial year 2025 · full format
2025
31-12
Financial Liquidity more than doubledcurrent ratio 2.21
Current ratio from 0.78 to 2.21.
03-12
Gazette deed Resignation: BDO Bedrijfsrevisoren (statutory auditor)
Permanent representative: Veerle Catry · Appointment: Finvision Bedrijfsrevisoren (statutory auditor)4 facts ▸
  • General meeting, 24-03-2025
  • Auditor resignation, BDO Bedrijfsrevisoren (statutory auditor)
  • Permanent representative, Veerle Catry
  • Auditor appointment, Finvision Bedrijfsrevisoren (statutory auditor)
10-10
Gazette deed Purpose · Amendment of the articles
General meeting1 fact ▸
  • General meeting, 30-09-2025
05-06
NBB filing Annual accounts filed
financial year 2024 · full format
14-03
Gazette deed Appointments: Wim Michiels (chair) and Mark Michiels (managing director)
4 facts ▸
  • Board meeting, 02-08-2024
  • Director appointment, Wim Michiels (chair)
  • Director appointment, Wim Michiels (managing director)
  • Director appointment, Mark Michiels (managing director)
2024
08-08
Gazette deed Incorporation
Demerger · Auditor report · Founding capital5 facts ▸
  • Incorporation, 28-06-2024
  • Demerger, “partiële splitsing, door oprichting van een nieuwe vennootschap” (deed in Dutch)
  • Other provision, “geen verslag partiële splitsing door bestuursorgaan en commissaris” (deed in Dutch)
  • Auditor report, “bedrijfsrevisor, verslag met betrekking tot de inbreng in natura in de nieuw op te richten vennootschap” (deed in Dutch)
  • Founding capital, €3,114,393.44
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
4 of 4 deeds read

Register details

Identification
Legal formPublic limited company
Founded29-07-2024
Financial year end31-12
Activities, NACEBEL 2025
20140Manufacture of chemicals and chemical products
72101Research and development on biotechnology
Contact
Phone +32498596680Hemiksem
E-invoicing
Reachable via Peppol
Peppol ID 0208:1011997238
Also 9925:BE1011997238
Registered 21-10-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 29 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Recognitions · licences · registrations

Food safety, FASFC

1 site
Hemiksemunit no. 2.362.052.245
2 permissions
Groententeeltbedrijf · since 10-09-2025
Authorisation · Fabrikant voedingssupplementen · since 07-08-2024

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Hemiksem · 1 establishment unit since 2024
registered office establishment The establishment unit on the map
Ground area
3,122 m²
Building footprint
369 m²
Building volume
2,060 m³
Parcel 11018B0152/00B003, Flanders · tallest building 6.6 m. Linked by address, not a title deed.
1 establishment unit
axabio
Nieuwe dreef 2, 2620 HemiksemResearch and development on biotechnology
since 2024unit no. 2.362.052.245
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
11018B0152/00B003 Flanders 3,122 m² 1 · 369 m² 6.6 m · 2
How the parcels are linked
Good to know
The parcel matches the address exactly.

Articles of association

PurposeThe activities the company may carry out under its articles.
“Het uitkeren of bezorgen van een rechtstreeks of onrechtstreeks vermogensvoordeel aan haar aandeelhouders; Middels haar bedrijfsvoering en…” (deed in Dutch)
2 activities (deed in Dutch)
  1. Het uitkeren of bezorgen van een rechtstreeks of onrechtstreeks vermogensvoordeel aan haar aandeelhouders.
  2. Middels haar bedrijfsvoering en economische activiteiten, een reële positieve impact te hebben op de samenleving en het milieu in het algemeen.

The full purpose is in the deed

Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
“Filip BEYERS” (deed in Dutch)
“Eric De Bie” (deed in Dutch)
1 more provision on this in the deed

Read from the deeds: 4 provisions, deed of 10-10-2025